P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales: Beauvais, D., Sourisseau, M., Béhal, H., Alfandari, S., Simon, N., Faure, E., Yakoub-Agha, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430048/
http://dx.doi.org/10.1097/01.HS9.0000848160.85133.ee
_version_ 1784779638936961024
author Beauvais, D.
Sourisseau, M.
Béhal, H.
Alfandari, S.
Simon, N.
Faure, E.
Yakoub-Agha, I.
author_facet Beauvais, D.
Sourisseau, M.
Béhal, H.
Alfandari, S.
Simon, N.
Faure, E.
Yakoub-Agha, I.
author_sort Beauvais, D.
collection PubMed
description
format Online
Article
Text
id pubmed-9430048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94300482022-08-31 P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Beauvais, D. Sourisseau, M. Béhal, H. Alfandari, S. Simon, N. Faure, E. Yakoub-Agha, I. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430048/ http://dx.doi.org/10.1097/01.HS9.0000848160.85133.ee Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Beauvais, D.
Sourisseau, M.
Béhal, H.
Alfandari, S.
Simon, N.
Faure, E.
Yakoub-Agha, I.
P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_full P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_fullStr P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_full_unstemmed P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_short P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_sort p1324: a risk-based strategy for the use of letermovir in cmv-positive recipients of allogeneic hematopoietic cell transplantation
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430048/
http://dx.doi.org/10.1097/01.HS9.0000848160.85133.ee
work_keys_str_mv AT beauvaisd p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT sourisseaum p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT behalh p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT alfandaris p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT simonn p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT fauree p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation
AT yakoubaghai p1324ariskbasedstrategyfortheuseofletermovirincmvpositiverecipientsofallogeneichematopoieticcelltransplantation

Ejemplares similares